Clinical Trial Execution OS
We have therapeutic ideas, but clinical trials are still slow, expensive, and operationally brittle.
The Stakes
Clinical trials are the throughput limiter for medicine. Every delay is delayed cures. Better execution reduces drug prices, increases R&D productivity, and expands access to trials for underrepresented populations.
Headline evidence
- •FDA guidance clarifies how decentralized elements can move trial activities to locations convenient for participants, while preserving oversight and data integrity. [1]
- •A 2024 analysis estimates direct daily costs to conduct phase II and III clinical trials are about $40,000 per day, underscoring the cost of delay. [2]
- •A 2024 site challenges report finds recruitment and retention remain a top constraint for sites, reflecting operational limits, not just scientific ones. [3]
Neglectedness
Why it stays neglected
Sponsors, contract research organizations, and sites have misaligned incentives and incompatible tooling. Data entry burdens persist because regulators require auditability. Recruitment is treated as marketing, not systems engineering. Health systems and trials often run as separate enterprises.
Tractability
High. Remote visits, eConsent, eSource, and better analytics are ready. AI can draft protocols, match eligibility, predict dropout, and automate monitoring signals. The hard part is compliance-grade integration, trust with regulators, and harmonizing across sites.
Startup surfaces
- Study startup automation:contracts, budgets, approvals, and site activation workflows
- •Participant matching and retention systems integrated into clinical care pathways
- •Risk-based monitoring platforms that reduce on-site monitoring while improving quality
- •Interoperable eSource and audit-trail tooling aligned to regulator expectations
- •“Trial-in-a-box” infrastructure for community clinics and low-resource settings
Source Stack (4)
- [1] FDA. Conducting Clinical Trials with Decentralized Elements (final guidance page). (fda.gov )
- [2] Smith ZP et al. New estimates on the cost of a delay day in drug development. (2024). (pubmed.ncbi.nlm.nih.gov )
- [3] WCG. 2024 Clinical Research Site Challenges Report (PDF). (wcgclinical.com )
- [4] Angus DC et al. Integrating clinical trials with practice of medicine (systems gap). (2024). (pmc.ncbi.nlm.nih.gov )
Builder Proof-of-Work
Community submitted artifacts, notes, and implementations for this idea.